We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-5.18%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$2.76B
AUM Growth
-$525M
Cap. Flow
-$439M
Cap. Flow %
-15.9%
Top 10 Hldgs %
38.29%
Holding
343
New
69
Increased
54
Reduced
100
Closed
111

Top Buys

Rank Stock Value
1
VRAY
ViewRay, Inc.
VRAY
+$17.9M
2
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$17.3M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$14.1M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$14M
5
CUTR
Cutera, Inc.
CUTR
+$12.7M

Top Sells

Rank Stock Value
1
SEER icon
Seer Inc
SEER
+$24.7M
2
MAPS
WM TECHNOLOGY INC A
MAPS
+$23.4M
3
LIVN icon
LivaNova
LIVN
+$20.2M
4
GKOS icon
Glaukos
GKOS
+$17.5M
5
COO icon
Cooper Companies
COO
+$16.3M

Sector Composition

Rank Sector Weight
1 Healthcare 29.75%
2 Consumer Staples 0.58%
3 Financials 0.5%
4 Consumer Discretionary 0.42%
5 Industrials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
151
DELISTED
Immunogen Inc
IMGN
$1.85M 0.07%
249,283
-93,765
-27% -$583K
UPC icon
152
Universe Pharmaceuticals Inc
UPC
$3.93M
$1.82M 0.07%
310
+236
+319% +$1.81M
SNAX
153
DELISTED
Stryve Foods, Inc. Class A Common Stock
SNAX
$1.73M 0.06%
29,170
-9,163
-24% -$657K
DALS
154
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$1.62M 0.06%
164,834
-35,166
-18% -$345K
PMGMU
155
DELISTED
Priveterra Acquisition Corp. Units
PMGMU
$1.56M 0.06%
157,759
-1,709
-1% -$17K
SRRA
156
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$1.55M 0.06%
71,320
-2,313
-3% -$51K
XENE icon
157
Xenon Pharmaceuticals
XENE
$6.31B
$1.51M 0.05%
48,502
-1,498
-3% -$44.8K
BHVN
158
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$1.5M 0.05%
+10,885
New +$1.38M
IONS icon
159
Ionis Pharmaceuticals
IONS
$9.39B
$1.48M 0.05%
+48,544
New +$1.53M
KDNY
160
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$1.47M 0.05%
90,241
+17,543
+24% +$250K
IRON icon
161
Disc Medicine
IRON
$3.09B
$1.44M 0.05%
16,434
-46
-0.3% -$4.51K
CYCN icon
162
Cyclerion Therapeutics
CYCN
$18.4M
$1.33M 0.05%
38,585
+17,469
+83% +$825K
LHDX
163
CALL
DELISTED
Lucira Health, Inc. Common Stock
LHDX
$1.27M 0.05%
+147,800
New +$940K
KURA icon
164
Kura Oncology
KURA
$882M
$1.25M 0.05%
89,612
+6,346
+8% +$103K
APRE icon
165
Aprea Therapeutics
APRE
$8.46M
$1.25M 0.05%
+21,693
New +$1.92M
PYXS icon
166
Pyxis Oncology
PYXS
$201M
$1.24M 0.04%
+112,762
New +$1.29M
CRVS icon
167
Corvus Pharmaceuticals
CRVS
$1.27B
$1.19M 0.04%
492,384
-241,884
-33% -$938K
ACAD icon
168
Acadia Pharmaceuticals
ACAD
$5.07B
$1.17M 0.04%
+50,000
New +$1.01M
RCOR
169
DELISTED
Renovacor, Inc.
RCOR
$1.16M 0.04%
150,505
-1,574
-1% -$13K
BLU
170
PUT
DELISTED
BELLUS Health Inc.
BLU
$1.14M 0.04%
141,700
+24,400
+21% +$162K
ABGI
171
DELISTED
ABG Acquisition Corp. I
ABGI
$1.14M 0.04%
116,070
-3,158
-3% -$30.9K
DCPH
172
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$1.12M 0.04%
114,945
+64,945
+130% +$1.22M
BEAM icon
173
Beam Therapeutics
BEAM
$2.76B
$1.11M 0.04%
13,978
-10,595
-43% -$907K
VINC
174
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.1M 0.04%
5,408
+2,418
+81% +$603K
ROIV icon
175
Roivant Sciences
ROIV
$26.1B
$1.05M 0.04%
+104,413
New +$869K
5 6
7
8 9

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2021 Portfolio in Review

As of Q4 2021, Pura Vida Investments held 343 positions worth $2.76B, down 16% from $3.29B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments withdrew a net $439M in Q4 2021, closing 111 positions and reducing 100 holdings. Its most notable exit was Seer Inc, an estimated $24.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 33% a quarter earlier, followed by Consumer Staples and Financials.

Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $15M.

  • Pura Vida Investments's largest Q4 2021 buy was BioMarin Pharmaceuticals: 170,210 shares worth $15M.
  • Pura Vida Investments added most to ViewRay, Inc. in Q4 2021, an estimated $17.9M increase.
  • Pura Vida Investments's biggest Q4 2021 reduction was LivaNova, cutting an estimated $20.2M.
  • Pura Vida Investments fully exited Seer Inc in Q4 2021, selling an estimated $24.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $2.76B portfolio in Q4 2021.
  • Pura Vida Investments opened 69 new positions and closed 111 in Q4 2021.
  • Pura Vida Investments's portfolio value fell 16% quarter-over-quarter to $2.76B.

Based on Pura Vida Investments's 13F filing for Q4 2021, filed 14 Feb 2022.